U.S. Semiconductors Stock News

Futu Holdings Limited recently received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting a shift toward more positive analyst earnings estimates and sentiment around its profit outlook. This change highlights how analyst estimate revisions can influence perceptions of Futu’s earnings power and the sustainability of its international, technology-led brokerage model. We’ll now examine how this Zacks Rank upgrade and brighter earnings outlook interact with Futu’s existing investment...

If you are wondering whether AbbVie at around US$214.98 is a fair deal or a stretch at current levels, this article walks through what the numbers are actually saying about the stock's value. The share price performance has been mixed, with a 3.8% gain over the last 7 days, an 8.2% decline over the last 30 days, a 6.2% decline year to date, an 8.3% return over 1 year, and very large gains of 49.0% and 147.4% across 3 and 5 years. Recent attention on AbbVie has focused on its position as a...

What BrightSpring’s recent performance data means for investors BrightSpring Health Services (BTSG) has attracted attention after recent trading data showed a 1.4% decline over the past day and a 6.2% pullback over the past week, alongside positive longer term returns. See our latest analysis for BrightSpring Health Services. Despite the recent 1-day and 7-day share price declines, BrightSpring’s 90-day share price return of 12.23% and very large 1-year total shareholder return of 131.19%...

The U.S. Justice Department has unsealed an indictment against three individuals linked to Super Micro Computer for allegedly diverting advanced Nvidia-powered servers worth about US$2.50 billions to Chinese customers in breach of U.S. export controls, triggering multiple shareholder class actions accusing the company of misleading disclosures on sales and compliance. Although Super Micro itself has not been named as a defendant, the involvement of a co-founder, governance upheaval, and...

Dianthus Therapeutics recently reported an early “GO” decision in its late-stage CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy, after meeting interim responder goals ahead of schedule. The US FDA also agreed to multiple company-proposed changes across claseprubart’s development program, including updated screening criteria, lab work, and autoimmune safety monitoring, potentially streamlining current and future studies. We’ll now examine how the early...

Hesai Group recently reported its fourth-quarter and full-year 2025 results, turning a prior-year loss into net income of CNY 435.88 million on CNY 3,027.57 million in sales, and entered a 2026 Supply of Products Framework Agreement under which it will provide LiDAR products and robotic actuators plus manufacturing and support services to Sharpa. By pairing improved profitability with a new Physical AI-focused partnership that bundles hardware and integration services, Hesai is broadening...

Arcutis Biotherapeutics (ARQT) is back in focus after new INTEGUMENT-INFANT Phase 2 data on ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, supporting a planned supplemental New Drug Application. See our latest analysis for Arcutis Biotherapeutics. The new clinical data arrives after a mixed stretch for the shares, with a 1-day share price return of 10.45% and 7-day share price return of 7.92% contrasting with a 30-day share price return decline of 12.64%. However, a...

IDEXX Laboratories (IDXX) has drawn fresh attention after introducing its IDEXX Cancer Dx Panel in the United Kingdom, offering blood test based early detection of lymphoma in at risk dogs and expanding its veterinary diagnostics reach. See our latest analysis for IDEXX Laboratories. Despite the product launch and earlier trading spikes, momentum in the share price has cooled, with a 30 day share price return of a 14.44% decline and a year to date share price return of a 16.13% decline, while...

If you are wondering whether Aflac at around US$109.64 is offering fair value or a potential bargain, this article walks through what the current price might be indicating. The stock has been relatively steady recently, with a 2.3% return over the last 7 days, a 3.3% decline over 30 days, and returns of 0.5% decline year to date and 0.2% decline over 1 year, set against much stronger 3 year and 5 year returns of 81.6% and 137.7%. Recent coverage around Aflac has focused on its role as a...

Wondering if Home Depot at around US$329.56 is priced for opportunity or caution? This article breaks down what the current share price might be telling you about value. The stock is down about 0.9% over the last week and 11.1% over the past month, with returns of a 4.7% decline year to date and an 8.9% decline over the last year, but still shows a 23.1% gain over three years and 19.2% over five years. These moves are unfolding against a backdrop where investors are paying close attention to...

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...

EQT (NYSE:EQT) is advancing its post Olympus Energy integration by preparing multi bench drilling across the Marcellus and Utica formations. The company is conducting field surveys in Upper Burrell, Pennsylvania, as it plans new lateral wells in previously untapped areas. This shift marks a move away from a single target drilling approach toward broader development of its Appalachian acreage. EQT, trading at $61.09, is entering this next phase after a period where attention largely centered...

In March 2026, EMCOR Group, Inc. was added to the FTSE All-World Index (USD), reflecting its growing relevance in global equity benchmarks. This index inclusion comes as EMCOR reports strong market share gains, higher returns on capital, and earnings per share growth outpacing its already solid revenue expansion. Next, we’ll examine how heightened investor interest ahead of EMCOR’s upcoming earnings report could influence the company’s investment narrative. We've uncovered the 12 dividend...

Advanced Energy Industries (AEIS) has drawn investor attention after a strong past 3 months, with total return around 54% and one year total return near 240%, prompting closer review of its fundamentals. See our latest analysis for Advanced Energy Industries. After a sharp run over the past year, with 1 year total shareholder return close to 240% and a 90 day share price return of about 54%, momentum has cooled in the last month, even though the share price closed at US$322.71 after an 8.2% 1...

Merck (NYSE:MRK) has entered into a collaboration with Infinimmune to use AI-driven antibody discovery and engineering technologies. The deal gives Merck exclusive rights to develop and commercialize human-derived antibody therapies for multiple diseases. For you as an investor, this move points to how Merck is trying to build out its biologics and immunology capabilities beyond its traditional small molecule and oncology focus. Infinimmune’s machine learning and single-cell immune...

LTC Properties (LTC), a real estate investment trust focused on seniors housing and health care properties, has been drawing attention as investors reassess its recent share performance and income profile following recent price moves. See our latest analysis for LTC Properties. The recent pullback, with a 1 month share price return showing a 6.35% decline from US$37.16, comes after a stronger run where the 3 year total shareholder return sits at 36.68%. This suggests that momentum has cooled...

A securities class action lawsuit was recently filed against Solaris Energy Infrastructure, Inc., alleging that between July 9, 2024 and March 17, 2025 the company misled investors about the prospects of its Mobile Energy Rentals LLC acquisition and overstated profitability metrics. The case raises questions about Solaris’s disclosure practices and financial reporting around a key acquisition, introducing potential legal, financial, and reputational risks for existing and prospective...

In early March 2026, Plug Power reported fiscal Q4 2025 results that showed revenue growth driven by higher equipment sales and ongoing commercial momentum across core markets, while management outlined plans for cost and efficiency gains aimed at positive 2026 EBITDAS. At the same time, a series of securities class action lawsuits over past disclosures on U.S. Department of Energy loan access and hydrogen project plans added a legal overhang that contrasts with management’s operational...

Keurig Dr Pepper has completed the roughly $25b acquisition of JDE Peet’s, adding more than 50 coffee brands to its portfolio. The company plans to split the combined business into two US listed entities, one focused on beverages and the other on coffee. A leadership reshuffle is underway, with new executives appointed to lead each future company. For investors watching NasdaqGS:KDP, this reshaping of the business comes after a challenging share price run. The stock trades at $26.33, with...

If you are wondering whether Philip Morris International is priced attractively at its current level, the key question is how its share price lines up with the value of its cash flows and assets. The stock last closed at US$165.34, with returns of 0.9% over 7 days, an 11.5% decline over 30 days, 3.1% year to date and 8.3% over the past year. These figures can change how investors think about both growth potential and risk. Recent news coverage has focused on Philip Morris International's...

Infinity Natural Resources (INR) has been drawing attention after recent trading swings, with the stock showing a mix of short term volatility and longer term moves that have left recent returns uneven for investors. See our latest analysis for Infinity Natural Resources. The recent pullback, with a 1 day share price return of a 4.55% decline to US$17.61, comes after a 19.55% 90 day share price return and a softer 1 year total shareholder return of a 4.81% decline. This suggests momentum has...

Why InterDigital stock is back on investor radar InterDigital (IDCC) is in focus after securing a preliminary injunction in Brazil against Transsion over alleged 5G patent infringement, a decision that directly affects device shipments in an important smartphone market. See our latest analysis for InterDigital. The injunction news follows a weaker 30-day share price return of a 17.6% decline and a year-to-date share price return of a 7.4% decline, set against a 1-year total shareholder return...

In late March 2026, AppLovin presented at the RSA Conference in San Francisco, where Global Head of Information Security & Compliance Jeremiah Kung discussed the company’s security and compliance approach. This appearance comes as AppLovin’s AI-powered advertising platform, strong recent revenue expansion, and significant free cash flow profile draw increased analyst attention alongside an ongoing SEC data practices probe. Next, we’ll examine how AppLovin’s RSA presence and regulatory...

Aurora Innovation recently used the Morgan Stanley Technology, Media, and Telecom Conference 2026 to outline past progress in driverless trucking, highlighting active driverless operations and plans to scale to hundreds of autonomous trucks across the Southern US by 2026. The company also highlighted partnerships with Roush Industries and Detmar Logistics and its push into adjacent opportunities such as ride-hailing and deliveries, signaling an effort to extend its autonomous driving...